These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 28244979)

  • 1. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.
    Gyurkocza B; Lazarus HM; Giralt S
    Bone Marrow Transplant; 2017 Aug; 52(8):1083-1090. PubMed ID: 28244979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
    Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia that is not in remission].
    Tachibana T
    Rinsho Ketsueki; 2021; 62(5):496-504. PubMed ID: 34248127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.
    Magenau J; Westervelt P; Khaled S; McGuirk J; Hari P; Eapen M; Becker PS; Parkin B; Braun T; Logan B; Wang H; Jagasia M; Rowley SD; Kim DD; Schechter T; Frey N; Scott B; Churay T; Lieland S; Forman S; Mineishi S
    Bone Marrow Transplant; 2017 Jan; 52(1):59-65. PubMed ID: 27427921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia.
    Schneidawind D; Federmann B; Faul C; Vogel W; Kanz L; Bethge WA
    Ann Hematol; 2013 Oct; 92(10):1389-95. PubMed ID: 23652585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?
    Song KW; Lipton J
    Bone Marrow Transplant; 2005 Aug; 36(3):183-91. PubMed ID: 15937497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
    Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
    Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia.
    Menon NN; Jenkins LM; Cui H; Jenkins C; Anwer F; Yeager AM; Katsanis E
    Ann Hematol; 2016 Mar; 95(4):637-44. PubMed ID: 26787415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia.
    Hamadani M; Mohty M; Kharfan-Dabaja MA
    Cancer Control; 2011 Oct; 18(4):237-45. PubMed ID: 21976242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of disease status on outcomes of allogeneic hematopoietic stem cell transplantation in patients with refractory and relapsed acute myeloid leukemia].
    Zhou QL; Tang XW; Sun AN; Qiu HY; Jin ZM; Miao M; Fu ZZ; Zhao BR; Shi XL; Chen GH; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):954-8. PubMed ID: 22931663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.
    Vu K; Manjappa S; DiPersio JF; Gao F; Westervelt P; Vij R; Stockerl-Goldstein KE; Uy GL; Abboud CN; Schroeder MA; Fehniger TA; Cashen AF; Romee R
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1425-30. PubMed ID: 25840336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.
    Yanada M
    Int J Hematol; 2015 Mar; 101(3):243-54. PubMed ID: 25212675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics.
    Yamasaki S; Yoshimoto G; Ogawa R; Aoki K; Higuchi M; Harada N; Arima F; Kondo S; Matubara F; Takahashi T; Uike N; Miyamoto T; Okamura S; Akashi K;
    Ann Hematol; 2015 Jul; 94(7):1159-65. PubMed ID: 25704584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
    Gomez-Arteaga A; Gyurkocza B
    Curr Opin Hematol; 2020 Mar; 27(2):115-121. PubMed ID: 31913152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant?
    Paubelle E; Ducastelle-Leprêtre S; Labussière-Wallet H; Nicolini FE; Barraco F; Plesa A; Salles G; Wattel E; Thomas X
    Ann Hematol; 2017 Mar; 96(3):363-371. PubMed ID: 28011984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia.
    Tang FF; Huang XJ; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang Y; Wang JZ; Yan CH; Sun YQ; Mo XD; Liu KY; Xu LP
    Leuk Res; 2016 Aug; 47():8-15. PubMed ID: 27239735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia.
    How J; Slade M; Vu K; DiPersio JF; Westervelt P; Uy GL; Abboud CN; Vij R; Schroeder MA; Fehniger TA; Romee R
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):648-653. PubMed ID: 28087457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.